Neurocrine CCO exercises 3,194 options, sells 2,154
Neurocrine Biosciences’ chief commercial officer exercised options and sold part of the resulting shares under a pre-established Rule 10b5-1 trading plan.
Rhea-AI Filing Summary
NEUROCRINE BIOSCIENCES INC (NBIX) reported that Chief Commercial Officer Eric Benevich exercised employee stock options and sold a portion of the resulting shares. On September 9, 2026, he exercised options for 3,194 shares of common stock at an exercise price of $43.24 per share, and on the same date sold 2,154 shares of common stock at $154.61 per share. The options had been granted on February 6, 2017 and were scheduled to expire on February 6, 2027. The sale was effected by a broker under a Rule 10b5-1 trading plan adopted by Mr. Benevich on June 10, 2026, and company policy restricts him from amending such plans after adoption. A separate footnote states that his reported holdings include 178 shares acquired through the company’s 2018 Employee Stock Purchase Plan.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and sale activity reported; no spread calculated
Exercise and Sale
3 txns
Insider
BENEVICH ERIC
Role
Chief Commercial Officer
Sold
2,154 shs ($333K)
Approx. gross sale proceeds
$333K
Approx. exercise cost
$138K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Incentive Stock Option F3 | 3,194 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 3,194 | $43.24 | $138K |
| Sale | Common Stock F2 | 2,154 | $154.61 | $333K |
Holdings After Transaction:
Incentive Stock Option — 0 contracts (Direct);
Common Stock — 64,408 shares (Direct)
Footnotes (3)
- F1. Includes an aggregate of 178 shares purchased on February 27, 2026 and August 31, 2026 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan.
- F2. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2026. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
- F3. The option was granted February 6, 2017 and vested in 48 equal monthly installments beginning March 6, 2017. These options were due to expire on February 6, 2027.
Key Figures
Options exercised: 3,194 shares
Option exercise price: $43.24 per share
Shares sold: 2,154 shares
+2 more
5 metrics
Options exercised
3,194 shares
Incentive stock options for Neurocrine Biosciences common stock exercised on September 9, 2026
Option exercise price
$43.24 per share
Exercise price of incentive stock options granted February 6, 2017 and exercised September 9, 2026
Shares sold
2,154 shares
Neurocrine Biosciences common stock sold on September 9, 2026 by the Chief Commercial Officer
Sale price
$154.61 per share
Per-share price for 2,154 Neurocrine Biosciences shares sold on September 9, 2026
ESPP shares included in holdings
178 shares
Shares purchased February 27, 2026 and August 31, 2026 under the 2018 Employee Stock Purchase Plan
Key Terms
Incentive Stock Option, Rule 10b5-1 trading plan, Employee Stock Purchase Plan
3 terms
Incentive Stock Option financial
"The option was granted February 6, 2017 and vested in 48 equal monthly installments"
An incentive stock option is a type of employee benefit that gives a worker the right to buy company shares at a fixed price, with special tax advantages if the employee holds the shares for a required period. Think of it as a coupon to buy future shares at today’s price that can result in lower tax on the gain. Investors care because ISOs can dilute share count, align staff incentives with the stock price, and affect company compensation costs and the timing of potential share sales.
Rule 10b5-1 trading plan regulatory
"effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Employee Stock Purchase Plan financial
"purchased on February 27, 2026 and August 31, 2026 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan"
An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.
FAQ
What insider transactions did NBIX’s Chief Commercial Officer report on September 9, 2026?
He exercised options for 3,194 shares of Neurocrine Biosciences common stock at $43.24 per share and sold 2,154 shares of common stock at $154.61 per share on September 9, 2026.
What options did the NBIX executive exercise in this Form 4?
He exercised an incentive stock option granted on February 6, 2017, covering 3,194 shares of Neurocrine Biosciences common stock at an exercise price of $43.24 per share. The option was scheduled to expire on February 6, 2027.
When were the exercised NBIX options originally granted and when were they due to expire?
The incentive stock options were granted on February 6, 2017, vested in 48 equal monthly installments beginning March 6, 2017, and were due to expire on February 6, 2027 before the reported exercise.
AI-generated analysis. How Rhea-AI works. Not financial advice.
